SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025.
Details of the events can be found below.
Wells Fargo 20th Annual Healthcare Conference
Format: 1x1 Meetings
Date: 09/05/2025
Location: Encore Boston Harbor, Everett, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: 09/08/2025
Location: Sheraton New York Times Square, New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat and 1x1 Meetings
Presenter: Mark Erlander, CEO
Date: 09/09/2025
Time: 10:30 AM ET
Location: Lotte New York Palace Hotel, New York, NY
Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Meghan Bianco
Taft Communications, a division of RF|Binder
609-544-5446
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.99 |
| Daily Change: | -0.11 -5.24 |
| Daily Volume: | 1,561,392 |
| Market Cap: | US$132.390M |
July 29, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
